By blocking both the 17α-hydroxylase and 17,20-lyase activities of CYP17A1, abiraterone markedly reduces the synthesis of testosterone and other androgens, including those produced inside the tumor, which are central drivers of CRPC progression [94]. This evidence concerns the gene CYP17A1 and neoplasm.